KAL/EVO-PAYMENTS
6.7.2021 10:02:13 CEST | Business Wire | Press release
KAL, the leading independent ATM software company, and EVO Payments, a leading global payments technology and services provider, have announced a new ATM service which is now available across Europe.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210706005181/en/
The solution combines KAL’s Kalignite software suite with EVO’s best-in-class payments infrastructure. It enables banks and IADs (independent ATM deployers) to rapidly deploy ATMs to any European location.
KAL’s multivendor software allows ATM deployers to select machines from over 40 vendors, while EVO’s infrastructure delivers the resilience and card scheme compliance expected from a world-class ATM solution.
The service allows a bank or IAD to choose any ATM type they want and any location across the EEA, Switzerland and the UK and deploy it with Visa/Mastercard acceptance at short notice. The solution includes the ATM software, the ATM host, the Visa/Mastercard acceptance and the clearing and settlement services. The bank or IAD simply has to make the hardware available and organise CIT cash in transit services.
KAL CEO Aravinda Korala says: “We are delighted to partner with EVO to bring banks and other ATM deployers this new solution. The service brings together proven technologies that guarantee ATM deployers an unprecedented level of flexibility and efficiency when responding to local market needs.”
Darren Wilson, President International at EVO Payments Inc., highlighted the new agreement between KAL and EVO, saying: “By combining EVO’s deep expertise and innovative approach as a global payments specialist with KAL’s world-class ATM software, we have created a highly efficient method of ATM deployment that is set to transform ATM networks across Europe.”
About KAL:
KAL is a world-leading ATM software company and preferred supplier to banks across the globe, including Citibank, UniCredit, Erste Česká, ING, OTP, HSBC and Westpac. KAL’s multivendor software gives banks full control of their ATM network, reducing costs, meeting security needs and improving competitiveness. It is installed and supported in more than 80 countries.
For more information, visit www.kal.com
About EVO Payments International:
EVO Payments International is part of the EVO Group and a full-service payment specialist for Germany and Europe. Founded in 1989, EVO is headquartered in Atlanta, U.S.A., and is a Principal Member of Visa and Mastercard. Its international presence spans North and Latin America as well as Europe. Cologne-based, EVO Payments International GmbH is the European subsidiary of the EVO Group.
Its range of services covers all aspects of cashless payment transactions in stationary retail and eCommerce – from acquiring (card acceptance), network operation and POS terminals to payment service providing and card acceptance at ATMs (Automated Teller Machines).
About EVO Payments, Inc.:
EVO Payments, Inc. (NASDAQ: EVOP) is a leading payment technology and services provider. EVO offers an array of innovative, reliable, and secure payment solutions to merchants, ranging from small and mid-size enterprises to multinational companies and organizations across the globe. As a fully integrated merchant acquirer and payment processor in over 50 markets and 150 currencies worldwide, EVO provides competitive solutions that promote business growth, increase customer loyalty, and enhance data security in the international markets it serves.
If you have any further questions, please do not hesitate to contact us. We will be happy to send you print-quality images on request.
More information at:
https://www.evopayments.eu/en/company/evo-news/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210706005181/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom